-
FDA wants more clinical trial data before approving Forest, Gedeon Richter psychiatric drug
NEW YORK — The Food and Drug Administration has declined to approve an experimental drug for schizophrenia and bipolar disorder developed by Forest Labs and Gedeon Richter, a Hungarian drug company, the two said Thursday.
The companies said the FDA issued a complete-response letter for cariprazine. The agency issues a complete-response letter when it has finished reviewing an application but issues remain that preclude final approval. In the letter, the FDA acknowledged the drug's efficacy, but wanted more clinical trial data.
-
Retailers, pharmacy trade and professional groups sponsor Capitol Hill health fair
WASHINGTON — More than six dozen pharmacists and pharmacy students from in and around the District of Columbia offered free health screenings on Capitol Hill Tuesday as a way to promote awareness of the role pharmacists play in the healthcare system.